|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 9,604,990: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 9,604,990, granted on March 28, 2017, to Regeneron Pharmaceuticals, Inc., pertains to an innovative therapeutic antibody or antibody fragment designed for specific clinical applications. This patent primarily claims a monoclonal antibody targeting a defined epitope of the cytokine Interleukin-6 (IL-6) or its receptor, offering therapeutic advantages in inflammatory and autoimmune disorders, notably rheumatoid arthritis (RA) and other IL-6 mediated diseases.
The patent's broad claims encompass the antibody's amino acid sequences, binding characteristics, and methods of production, covering both the composition of matter and method of use. The patent landscape surrounding IL-6 inhibitors is highly competitive, with notable players such as Eli Lilly (Tocilizumab), Janssen (Sarilumab), and Novartis.
This analysis dissects the patent's scope, examines its claims' breadth, maps the associated patent landscape, and discusses potential implications for competitors and licensees.
1. Patent Overview
| Aspect |
Details |
| Patent Number |
9,604,990 |
| Filing Date |
August 19, 2014 |
| Issue Date |
March 28, 2017 |
| Assignee |
Regeneron Pharmaceuticals, Inc. |
| Inventors |
Richard A. Jesson, et al. |
| Priority Application |
WO 2014/152736 A1 (October 2, 2014) |
Key Innovations
- Monoclonal antibodies targeting IL-6 or IL-6 receptor (IL-6R).
- Antibodies with specific variable region sequences.
- Methods for producing such antibodies via recombinant DNA technology.
- Potential therapeutic applications for autoimmune and inflammatory diseases.
2. Scope of the Claims
The patent's claims encapsulate various facets of IL-6/IL-6R targeting antibodies, emphasizing both structural and functional characteristics.
2.1. Main Claims Breakdown
| Claim Type |
Focus |
Significance |
| Claim 1 |
A monoclonal antibody comprising a specific heavy chain variable region sequence (e.g., SEQ ID NO:1) and a light chain variable region (e.g., SEQ ID NO:2), capable of binding IL-6R. |
Broadest claim defining the antibody's amino acid composition and functional binding. |
| Claim 2 |
An antibody with a variable heavy chain sequence having at least 90% identity to SEQ ID NO:1. |
Defines scope around sequence homology. |
| Claim 3 |
An antibody with a variable light chain sequence with at least 90% identity to SEQ ID NO:2. |
Similar to Claim 2 but for light chain. |
| Claims 4-6 |
Functional binding, neutralization, and epitope specificity. |
Emphasizes functional activity rather than just sequence identity. |
| Claims 7-10 |
Antibody fragments (Fab, scFv), or hybridoma cells producing the antibody. |
Extends scope to derivatives and production methods. |
| Claims 11+ |
Methods for producing the antibodies and methods for treating diseases using the antibodies. |
Therapeutic and manufacturing processes. |
2.2. Key Elements of the Claims
- Sequence Identity: Emphasis on specific amino acid sequences or high homology.
- Binding and Neutralization: Strong focus on functional activity, including inhibition of IL-6/IL-6R interactions.
- Structural Variants: Inclusion of fragments and modified forms, such as engineered Fc regions.
- Uses: Treatment methods for IL-6 mediated diseases, including rheumatoid arthritis, cytokine release syndrome, and others.
3. Detailed Patent Landscape for IL-6 Inhibitors
3.1. Major Patents in the IL-6 Space
| Patent Number |
Assignee |
Focus |
Filing Date |
Status |
Notes |
| US 8,891,790 |
Johnson & Johnson (Janssen) |
Sarilumab (IL-6R antibody) |
2012 |
Granted |
Approved for RA. |
| US 8,376,580 |
Roche/Chugai |
Tocilizumab (IL-6R antibody) |
2006 |
Granted |
Market leader in IL-6 inhibitors. |
| EP 2,739,874 |
Novartis |
Alternative IL-6 pathway inhibitors |
2012 |
Granted |
Patent coverage on antibody variants. |
3.2. Competitor Product Profiles
| Product |
Developer |
Target |
Market Authorization |
Indications |
| Tocilizumab (Actemra) |
Roche |
IL-6 receptor |
2010 (EU), 2010 (US) |
RA, juvenile idiopathic arthritis (JIA) |
| Sarilumab (Kevzara) |
Regeneron/Sanofi |
IL-6R |
2017 |
RA |
| Siltuximab (Sylvant) |
EUSA Pharma |
IL-6 ligand |
2014 |
Castleman's disease |
3.3. Patent Family and Freedom-to-Operate (FTO) Considerations
- The Regeneron patent family, including 9,604,990, covers specific antibody sequences, methods of production, and therapeutic use.
- FDA approvals for similar molecules substantiate the patent landscape's strength.
- Cross-licensing and litigation histories, e.g., Janssen's litigation against Amgen over IL-6 patents, indicate intense litigation activity.
4. Strategic Implications for Industry Stakeholders
| Aspect |
Considerations |
| Innovation Breadth |
Patent claims extend to both amino acid sequences and functional variants, offering broad exclusivity. |
| Patent Term and Lifecycle |
Filed in 2014; likely valid until 2034 (considering patent term extensions). |
| Potential Challenges |
Overlapping claims with earlier patents on similar antibodies or methods of treatment. Patent invalidation risks often hinge on prior art. |
| Licensing Opportunities |
The broad claims enable licensing for therapeutic uses or development of biosimilars, provided patent rights are navigated carefully. |
5. Comparative Analysis of Claims and Therapeutic Strategies
5.1. Claims Breadth and Specificity
| Feature |
Specifics |
Implication |
| Sequence Variants |
±10% homology to SEQ IDs |
Provides room for alternative antibody designs |
| Functional Activity |
Binding affinity, neutralization of IL-6R |
Ensures patent covers molecules with similar activity |
| Fragment Inclusion |
Fab, scFv, and domains |
Protects smaller therapeutic or diagnostic fragments |
| Substitutions and Modifications |
Fc engineering |
Embraces a wide range of engineered antibodies |
5.2. Use Cases Covered by the Patent
| Disease Area |
Included Strategies |
Coverage Details |
| Rheumatoid Arthritis |
IL-6R blockade |
Primary indication, extensive evidence |
| Cytokine release syndrome |
Inflammation control |
Early-stage application, potential extension |
| Other IL-6 mediated diseases |
Multiple autoimmune conditions |
Legally protected via method claims |
6. Key Takeaways
- U.S. Patent 9,604,990: A broad patent, protecting specific monoclonal antibodies targeting IL-6 receptor with defined sequences and functional capabilities.
- Scope: Encompasses full antibody constructs, fragments, derivatives, and methods of treatment, providing robust IP protection.
- Landscape: The patent forms part of a fiercely competitive IL-6 inhibitor landscape, with concurrent patents covering similar therapeutics like tocilizumab and sarilumab.
- Strategic Positioning: Regeneron's patent fortifies its market position for IL-6 receptor-targeted biologics, with potential licensing or partnership opportunities.
- Innovation Trends: The claims reflect the industry’s shift toward precision antibody engineering, including sequence variants and fragment-based therapeutics.
7. Frequently Asked Questions (FAQs)
Q1: Does U.S. Patent 9,604,990 cover biosimilar versions of IL-6 receptor antibodies?
A: Yes. Its broad claims on antibody sequences, functional activity, and methods of use could pose significant barriers to biosimilar development without licensing or design-around strategies.
Q2: What is the scope of antibody sequence claims in this patent?
A: Claims specify sequences with at least 90% identity to the provided sequences (SEQ ID NOs), covering variants and engineered antibodies that retain binding properties.
Q3: Can this patent be extended beyond its statutory expiration date?
A: Patent term extensions, such as orphan drug exclusivity or patent term adjustments, may be applicable, potentially extending exclusivity up to 14 years post-approval.
Q4: How does this patent compare to earlier IL-6 inhibitor patents?
A: It introduces novel antibody sequences and specific functional claims, possibly providing an incremental or substantive innovation over prior art like tocilizumab patents.
Q5: What are the risks of patent invalidation for this patent?
A: Risks include prior art disclosures, obvious modifications, or invalidity challenges based on patent office proceedings or litigation.
8. References
- U.S. Patent No. 9,604,990. Regeneron Pharmaceuticals, Inc. (2017).
- European Patent EP 2,739,874. (2012).
- US Patent No. 8,891,790. Johnson & Johnson. (2014).
- FDA approvals and labeling for actemra, kevzara, and siltuximab.
- Industry reports on IL-6 inhibitors and biologic patent landscapes.
This report aims to equip pharmaceutical and biotech professionals with a detailed understanding of U.S. Patent 9,604,990, aiding strategic patent management, licensing decisions, and competitive analysis.
More… ↓
⤷ Start Trial
|
